News

Agilent Technologies has introduced GeneSpring GX 11, the latest generation of its desktop software for visualising and analysing microarray data, and GeneSpring Workgroup 11, the enterprise version of

Boehringer Ingelheim has reported results from the Recover study investigating Dabigatran Etexilate (150 mg BID), a direct thrombin inhibitor (DTI), compared to dose-adjusted Warfarin in patients with acute

Alexion PharmaceuticalsSoliris (eculizumab) developed by Alexion, a first-in-class terminal complement inhibitor, was found to reduce hemolysis and transfusion requirements, and improved measures of fatigue, when added to ongoing

Amgen has presented results from the studies on the safety and efficacy of Nplate (Romiplostim) in adult patients with myelodysplastic syndromes (MDS). The results of the studies were

Gloucester has presented preclinical data, which demonstrates that the combination of Istodax (Romidepsin) and Velcade (Bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin’s lymphoma cell lines. Istodax

The FDA has approved Lilly’s Zyprexa (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder

Allos Therapeutics (Allos) has entered into a collaborative agreement with Idis, to manage the named patient program for Folotyn (pralatrexate injection) outside of the US. The FDA has

Watson Pharmaceuticals (Watson) has confirmed that its subsidiary, Watson Laboratories has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market its 8mg Ramelteon

The FDA has approved once-daily AstraZeneca’s Seroquel XR (quetiapine fumarate) extended release tablets as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD). In addition to